Abstract: The present invention relates to the structure of Fab 4E10, e.g., as a complex with herein identified peptide KGND, herein identified as a 4E10 mimetope on gp41, as determined by crystallographic techniques, and the confirmation that peptide KGND has a functional relevant conformation, as well as the determination of key residues on 4E10, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides which bind to Fab 4E10.

Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPSc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.

Abstract: Methods are disclosed whereby formulations of molecules are administered rendering cells resistant to infection with infectious proteins such as prions. The formulation preferably comprises a plurality of Fab fragments which (1) recognize and selectively bind to a range of epitopes on the protein of interest, (e.g. epitopes on PrPC) and (2) bind to epitopes which interrupt the chain of events resulting in a change of the protein's conformation to an infectious disease conformation of the protein. The molecules and formulation are also useful in clearing infectious proteins from cells.

Abstract: It has been discovered that one of the causes of human rheumatoid arthritis is an autoimmune reaction to human glucose-6-phosphate isomerase. While human glucose-6-phosphate isomerase is a normal constituent of living tissue, and the underlying reasons for the autoimmune reaction are not understood, this discovery enables effective treatment of the disease, especially when the human immune reaction is the primary cause of the rheumatoid arthritis. The human antibody, anti-glucose-6-phosphate isomerase IgG, can be used to develop immunopolypeptides having binding capacity with the antigen. Antibodies and antibody fragments to the antiglucose-6-phosphate isomerase IgG, antisense oligonucleotides, conjugates of human GPI with cytotoxic agents, immobilized human GPI may be used to ameliorate or eliminate the immune reaction. The peptide, nucleotide products as well as methods of diagnosis and treatment are provided.

Abstract: Methods for random or rational design of high affinity domain exchanged binding molecules and methods of use are provided herein. Also provided are libraries containing a plurality of such domain exchanged binding molecules.

Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.

Abstract: A reprogrammable logic array is characterized by the use of a RAM fuse to selectively control the transfer of variable from input lines to intersecting output combination lines of the array. The configuration of the combiner array is programmed by writing to all of the RAM locations that are associated with the array. If a connection is to be made, a logical "1" is written to the RAM cell for that connection and if no connection is desired, a "0" is written to the RAM cell. The array which includes a novel input interface, can be quickly and easily reprogrammed simply by writing to the appropriate RAM cells. The RAM fuses may function as standard static RAM if the device does not need to function as a combiner.